Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.6024
-0.0030 (-0.50%)
Apr 22, 2026, 4:00 PM EDT - Market closed
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $303.00K in the quarter ending December 31, 2025, with 29.49% growth. This brings the company's revenue in the last twelve months to $914.50K, up 31.02% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.
Revenue (ttm)
$914.50K
Revenue Growth
+31.02%
P/S Ratio
30.25
Revenue / Employee
$13,373
Employees
59
Market Cap
23.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | - |
| Mar 31, 2023 | -227.00K | -1.34M | - |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Mar 31, 2018 | - | - | - |
| Mar 31, 2017 | 1.25M | - | - |
| Mar 31, 2016 | - | - | - |
| Mar 31, 2015 | - | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | 200.40K | -1.14M | -85.07% |
| Mar 31, 2012 | 1.34M | -728.80K | -35.19% |
| Mar 31, 2011 | 2.07M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| VYNE Therapeutics | 570.00K |
| Exicure | 500.00K |
| Lexaria Bioscience | 368.00K |
| Allarity Therapeutics | 320.00K |
| Serina Therapeutics | 130.00K |
VTGN News
- 19 hours ago - Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - Business Wire
- 6 weeks ago - Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline - GlobeNewsWire
- 7 weeks ago - Vistagen to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference - Business Wire
- 2 months ago - Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update - Business Wire
- 2 months ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics - Newsfile Corp
- 2 months ago - VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel - GlobeNewsWire
- 2 months ago - Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 - Business Wire